Home  /  Resource Library  /  RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Results of a study comparing tafasitamab combined with lenalidomide with lenalidomide alone for treatment of relapsed DLBCL.